SEEK TO CURE
The Biotherapeutics Development Group focuses on several areas: (1) discovering and developing new monoclonal antibodies (mAbs), (2) scale-up production of extracellular vesicles, and (3) synthesizing nucleic acids using cell-free approaches. We have established the Antibody Development Platform (ADP) which facilitates the generation of novel mAbs toward cell surface markers and unique glycan structures found on stem cells and cancer cells. We also have a GMP-compliant extracellular vesicle manufacturing platform suitable for clinical applications. Additionally, we are developing innovative enzymatic methods to synthesize nucleic acids.
- Antibody discovery and development
- Cell-based assay development for functional evaluation of biotherapeutics
- Extracellular vesicle manufacturing for preclinical to clinical applications
- Capability development for cell-free nucleic acid synthesis
A*STAR celebrates International Women's Day
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM